Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001551986-18-000017)

Filing Details

Accession Number:: 0001551986-18-000017
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-08-28 16:33:09
Reporting Period:: 2018-08-24

Accepted Time:: 2018-08-28 16:33:09
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1551986	Innovate Biopharmaceuticals Inc.	INNT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1492647	Sherie June Almenoff	C/O Innovate Biopharmaceuticals, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NC 27615	Coo And Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-08-24	100	$4.85	100	No	4	P	Indirect	By Meadowlark Management LLC
Common Stock	Acquisiton	2018-08-24	400	$4.99	500	No	4	P	Indirect	By Meadowlark Management LLC
Common Stock	Acquisiton	2018-08-27	47	$4.90	547	No	4	P	Indirect	By Meadowlark Management LLC
Common Stock	Acquisiton	2018-08-27	253	$4.96	800	No	4	P	Indirect	By Meadowlark Management LLC
Common Stock	Acquisiton	2018-08-27	100	$4.94	900	No	4	P	Indirect	By Meadowlark Management LLC
Common Stock	Acquisiton	2018-08-24	500	$4.85	1,400	No	4	P	Indirect	By Meadowlark Management LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By Meadowlark Management LLC
No	4	P	Indirect	By Meadowlark Management LLC
No	4	P	Indirect	By Meadowlark Management LLC
No	4	P	Indirect	By Meadowlark Management LLC
No	4	P	Indirect	By Meadowlark Management LLC
No	4	P	Indirect	By Meadowlark Management LLC

Footnotes

The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.